

ZENZEDI - dextroamphetamine sulfate tablet
Azurity Pharmaceuticals, Inc.

ZENZEDI[®] (DEXTROAMPHETAMINE SULFATE TABLETS, USP) CII

Rx only


WARNING: ABUSE, MISUSE, AND ADDICTION

Dextroamphetamine sulfate has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including dextroamphetamine sulfate, can result in overdose and death (see OVERDOSAGE), and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.

Before prescribing dextroamphetamine sulfate, assess each patient's risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout dextroamphetamine sulfate treatment, reassess each patient's risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction (see WARNINGS and DRUG ABUSE and DEPENDENCE).

DESCRIPTION

Dextroamphetamine sulfate, USP is the dextro isomer of the compound *d,l*-amphetamine sulfate, a sympathomimetic amine of the amphetamine group. Chemically, dextroamphetamine is *d*-alpha-methylphenethylamine, and is present in all forms of dextroamphetamine sulfate, USP as the neutral sulfate. The structural formula is as follows:



$(C_9H_{13}N)_2 \cdot H_2SO_4$ M.W. 368.49

Inactive Ingredients

Each tablet, for oral administration, contains dextroamphetamine sulfate, USP in either 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg or 30 mg. Each tablet also contains the following inactive ingredients: colloidal silicon dioxide, crospovidone, microcrystalline cellulose and stearic acid.

The 5 mg tablets also contain D&C Red #27 and FD&C Yellow #6. The 7.5 mg tablets also contain FD&C Blue #1 and D&C Yellow #10. The 10 mg tablets also contain FD&C

Red #40, FD&C Yellow #6 and FD&C Blue #2. The 15 mg tablets also contain FD&C Blue #1, FD&C Blue #2, and FD&C Red #40. The 20 mg tablets also contain FD&C Blue #1 and D&C Red #27. The 30 mg tablets also contain D&C Yellow #10.

CLINICAL PHARMACOLOGY

Amphetamines are non-catecholamine, sympathomimetic amines with CNS stimulant activity. Peripheral actions include elevations of systolic and diastolic blood pressures and weak bronchodilator and respiratory stimulant action.

There is neither specific evidence which clearly establishes the mechanism whereby amphetamines produce mental and behavioral effects in children, nor conclusive evidence regarding how these effects relate to the condition of the central nervous system.

Pharmacokinetics

The pharmacokinetics of the tablet and sustained-release capsule were compared in 12 healthy subjects. The extent of bioavailability of the sustained-release capsule was similar compared to the immediate-release tablet. Following administration of three 5 mg tablets, average maximal dextroamphetamine plasma concentrations (C_{max}) of 36.6 ng/mL were achieved at approximately 3 hours. Following administration of one 15 mg sustained-release capsule, maximal dextroamphetamine plasma concentrations were obtained approximately 8 hours after dosing. The average C_{max} was 23.5 ng/mL. The average plasma $T_{1/2}$ was similar for both the tablet and sustained-release capsule and was approximately 12 hours.

In 12 healthy subjects, the rate and extent of dextroamphetamine absorption were similar following administration of the sustained-release capsule formulation in the fed (58 to 75 gm fat) and fasted state.

INDICATIONS AND USAGE

Zenzedi[®] (Dextroamphetamine Sulfate Tablets, USP) is indicated for:

1. **Narcolepsy.**
2. **Attention Deficit Disorder with Hyperactivity**, as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in pediatric patients (ages 3 to 16 years) with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted.

CONTRAINDICATIONS

Known hypersensitivity to amphetamine products.

During or within 14 days following the administration of monoamine oxidase inhibitors (hypertensive crises may result).

WARNINGS

Abuse, Misuse, and Addiction

Dextroamphetamine sulfate has a high potential for abuse and misuse. The use of dextroamphetamine sulfate exposes individuals to the risks of abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Amphetamine sulfate can be diverted for non-medical use into illicit channels or distribution (see DRUG ABUSE and DEPENDENCE). Misuse and abuse of CNS stimulants, including dextroamphetamine sulfate, can result in overdose and death (see OVERDOSAGE), and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.

Before prescribing dextroamphetamine sulfate, assess each patient's risk for abuse, misuse, and addiction. Educate patients and their families about these risks and proper disposal of any unused drug. Advise patients to store amphetamine sulfate in a safe place, preferably locked, and instruct patients to not give dextroamphetamine sulfate to anyone else. Throughout dextroamphetamine sulfate treatment, reassess each patient's risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction.

Risks to Patients with Serious Cardiac Disease

Sudden death has been reported in patients with structural cardiac abnormalities or other serious cardiac disease who are treated with CNS stimulants at the recommended ADHD dosages.

Avoid dextroamphetamine sulfate use in patients with known structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmia, coronary artery disease, or other serious cardiac disease.

Increased Blood Pressure and Heart Rate

CNS stimulants cause an increase in blood pressure (mean increase about 2 to 4 mm Hg) and heart rate (mean increase about 3 to 6 bpm). Monitor all patients for potential tachycardia and hypertension.

Psychiatric Adverse Reactions

Exacerbation of Pre-Existing Psychosis

CNS stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a pre-existing psychotic disorder.

Induction of a Manic Episode in Patients with Bipolar Disorder

CNS stimulants may induce a manic or mixed episode in patients. Prior to initiating treatment, screen patients for risk factors for developing a manic episode (e.g.,

comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, or depression).

New Psychotic or Manic Symptoms

CNS stimulants, at recommended doses, may cause psychotic or manic symptoms (e.g., hallucinations, delusional thinking, or mania) in patients without a prior history of psychotic illness or mania. In a pooled analysis of multiple short-term, placebo-controlled studies of CNS stimulants, psychotic or manic symptoms occurred in approximately 0.1% of CNS stimulant-treated patients, compared with 0% of placebo-treated patients. If such symptoms occur, consider discontinuing dextroamphetamine sulfate.

Long-Term Suppression of Growth in Pediatric Patients

CNS stimulants have been associated with weight loss and slowing of growth rate in pediatric patients, including dextroamphetamine sulfate. Closely monitor growth (weight and height) in dextroamphetamine sulfate -treated pediatric patients treated with CNS stimulants.

Pediatric patients who are not growing or gaining height or weight as expected may need to have their treatment interrupted (see PRECAUTIONS, PEDIATRIC USE).

Seizures

There is some clinical evidence that stimulants may lower the convulsive threshold in patients with prior history of seizures, in patients with prior EEG abnormalities in absence of seizures, and, very rarely, in patients without a history of seizures and no prior EEG evidence of seizures. In the presence of seizures, the drug should be discontinued.

Peripheral Vasculopathy, Including Raynaud's Phenomenon

Stimulants, including dextroamphetamine sulfate tablets, used to treat ADHD are associated with peripheral vasculopathy, including Raynaud's phenomenon. Signs and symptoms are usually intermittent and mild; however, very rare sequelae include digital ulcerations and/or soft tissue breakdown. Effects of peripheral vasculopathy, including Raynaud's phenomenon, were observed in post-marketing reports at the therapeutic dosages of CNS stimulants in all age groups throughout the course of treatment. Signs and symptoms generally improved after dosage reduction or discontinuation of the CNS stimulant. Careful observation for digital changes is necessary during dextroamphetamine sulfate tablet-treatment. Further clinical evaluation (e.g., rheumatology referral) may be appropriate for dextroamphetamine sulfate tablet-treated patients who develop signs or symptoms of peripheral vasculopathy.

Serotonin Syndrome

Serotonin syndrome, a potentially life-threatening reaction, may occur when amphetamines are used in combination with other drugs that affect the serotonergic neurotransmitter systems such as monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John's Wort (see **Drug Interactions**). The co-administration of cytochrome P450 (CYP2D6) inhibitors may also increase the risk with increased

exposure to dextroamphetamine sulfate tablets. In these situations, consider an alternative non-serotonergic drug or an alternative drug that does not inhibit CYP2D6 (see **Drug Interactions**).

Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea).

Concomitant use of dextroamphetamine sulfate tablets with MAOI drugs is contraindicated (see **CONTRAINDICATIONS**).

Discontinue treatment with dextroamphetamine sulfate tablets and any concomitant serotonergic agents immediately if the above symptoms occur, and initiate supportive symptomatic treatment. If concomitant use of dextroamphetamine sulfate tablets with other serotonergic drugs or CYP2D6 inhibitors is clinically warranted, initiate dextroamphetamine sulfate tablets with lower doses, monitor patients for the emergence of serotonin syndrome during drug initiation or titration, and inform patients of the increased risk for serotonin syndrome.

Motor and Verbal Tics, and Worsening of Tourette's Syndrome

CNS stimulants, including dextroamphetamine sulfate, have been associated with the onset or exacerbation of motor and verbal tics. Worsening of Tourette's syndrome has also been reported. Assess the family history and clinically evaluate patients for tics or Tourette's syndrome before initiating dextroamphetamine sulfate. Regularly monitor patients for the emergence or worsening of tics or Tourette's syndrome with dextroamphetamine sulfate, and discontinue treatment if clinically appropriate.

PRECAUTIONS

Information for Patients

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Abuse, Misuse, and Addiction

Educate patients and their families about the risks of abuse, misuse, and addiction of dextroamphetamine sulfate, which can lead to overdose and death, and proper disposal of any unused drug (see *WARNINGS, DRUG ABUSE AND DEPENDENCE, and OVERDOSAGE*). Advise patients to store dextroamphetamine sulfate in a safe place, preferably locked, and instruct patients to not give dextroamphetamine sulfate to anyone else.

Risks to Patients with Serious Cardiac Disease

Advise patients that there are potential risks to patients with serious cardiac disease, including sudden death, with dextroamphetamine sulfate use. Instruct patients to contact a healthcare provider immediately if they develop symptoms such as exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease (see

WARNINGS).

Increased Blood Pressure and Heart Rate

Advise patients that dextroamphetamine sulfate can elevate blood pressure and heart rate (*see WARNINGS*).

Psychiatric Adverse Reactions

Advise patients that dextroamphetamine sulfate, at recommended doses, can cause psychotic or manic symptoms, even in patients without prior history of psychotic symptoms or mania (*see WARNINGS*).

Long-Term Suppression of Growth in Pediatric Patients

Advise patients that dextroamphetamine sulfate, may cause slowing of growth including weight loss (*see WARNINGS*).

Circulation problems in fingers and toes [Peripheral vasculopathy, including Raynaud's phenomenon]

- Instruct patients beginning treatment with dextroamphetamine sulfate tablets about the risk of peripheral vasculopathy, including Raynaud's Phenomenon, and associated signs and symptoms: fingers or toes may feel numb, cool, painful, and/or may change color from pale, to blue, to red.
- Instruct patients to report to their physician any new numbness, pain, skin color change, or sensitivity to temperature in fingers or toes.
- **Instruct patients to call their physician immediately with any signs of unexplained wounds appearing on fingers or toes while taking dextroamphetamine sulfate tablets.**
- Further clinical evaluation (e.g., rheumatology referral) may be appropriate for certain patients.

Serotonin Syndrome

Caution patients about the risk of serotonin syndrome with concomitant use of dextroamphetamine sulfate and other serotonergic drugs including SSRIs, SNRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St. John's Wort, and with drugs that impair metabolism of serotonin (in particular MAOIs, both those intended to treat psychiatric disorders and also others such as linezolid [*see CONTRAINDICATIONS, WARNINGS, and DRUG INTERACTIONS*]). Advise patients to contact their healthcare provider or report to the emergency room if they experience signs or symptoms of serotonin syndrome.

Motor and Verbal Tics, and Worsening of Tourette's Syndrome

Advise patients that motor and verbal tics and worsening of Tourette's Syndrome may occur during treatment with dextroamphetamine sulfate. Instruct the patients to notify their healthcare provider if emergence or worsening of tics or Tourette's syndrome occurs (*see WARNINGS*).

Amphetamines may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or vehicles; the patient should therefore be cautioned accordingly.

Drug Interactions

MAO Inhibitors

MAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism. This slowing potentiates amphetamines, increasing their effect on the release of norepinephrine and other monoamines from adrenergic nerve endings; this can cause headaches and other signs of hypertensive crisis. A variety of neurological toxic effects and malignant hyperpyrexia can occur, sometimes with fatal results.

Serotonergic Drugs

The concomitant use of dextroamphetamine sulfate tablets and serotonergic drugs increases the risk of serotonin syndrome. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during dextroamphetamine sulfate tablets initiation or dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine sulfate tablets and the concomitant serotonergic drug(s) (see **WARNINGS** and **PRECAUTIONS**). Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St. John's Wort.

CYP2D6 Inhibitors

The concomitant use of dextroamphetamine sulfate tablets and CYP2D6 inhibitors may increase the exposure of dextroamphetamine sulfate tablets compared to the use of the drug alone and increase the risk of serotonin syndrome. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome particularly during dextroamphetamine sulfate tablets initiation and after a dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine sulfate tablets and the CYP2D6 inhibitor (see **WARNINGS, OVERDOSAGE**).

Acidifying Agents

Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines. Urinary acidifying agents (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion. Both groups of agents lower blood levels and efficacy of amphetamines.

Adrenergic Blockers

Adrenergic blockers are inhibited by amphetamines.

Alkalinizing Agent

Gastrointestinal alkalinizing agents (sodium bicarbonate, etc.) increase absorption of amphetamines. Urinary alkalinizing agents (acetazolamide, some thiazides) increase the concentration of the non-ionized species of the amphetamine molecule, thereby decreasing urinary excretion. Both groups of agents increase blood levels and therefore potentiate the actions of amphetamines.

Antidepressants, Tricyclic

Amphetamines may enhance the activity of tricyclic or sympathomimetic agents; *d*-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of *d*-amphetamine in the brain; cardiovascular effects can be potentiated.

Antihistamines

Amphetamines may counteract the sedative effect of antihistamines.

Antihypertensives

Amphetamines may antagonize the hypotensive effects of antihypertensives.

Chlorpromazine

Chlorpromazine blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines, and can be used to treat amphetamine poisoning.

Ethosuximide

Amphetamines may delay intestinal absorption of ethosuximide.

Haloperidol

Haloperidol blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines.

Lithium Carbonate

The stimulatory effects of amphetamines may be inhibited by lithium carbonate.

Meperidine

Amphetamines potentiate the analgesic effect of meperidine.

Methenamine Therapy

Urinary excretion of amphetamines is increased, and efficacy is reduced, by acidifying agents used in methenamine therapy.

Norepinephrine

Amphetamines enhance the adrenergic effect of norepinephrine.

Phenobarbital

Amphetamines may delay intestinal absorption of phenobarbital; co-administration of phenobarbital may produce a synergistic anticonvulsant action.

Phenytoin

Amphetamines may delay intestinal absorption of phenytoin; co-administration of phenytoin may produce a synergistic anticonvulsant action.

Propoxyphene

In cases of propoxyphene overdose, amphetamine CNS stimulation is potentiated and fatal convulsions can occur.

Veratrum Alkaloids

Amphetamines inhibit the hypotensive effect of veratrum alkaloids.

Drug/Laboratory Test Interactions

- Amphetamines can cause a significant elevation in plasma corticosteroid levels. This increase is greatest in the evening.
- Amphetamines may interfere with urinary steroid determinations.

Carcinogenesis/Mutagenesis

Mutagenicity studies and long-term studies in animals to determine the carcinogenic potential of dextroamphetamine sulfate have not been performed.

Pregnancy

Teratogenic Effects

Pregnancy Category C

Dextroamphetamine has been shown to have embryotoxic and teratogenic effects when administered to A/Jax mice and C57BL mice in doses approximately 41 times the maximum human dose. Embryotoxic effects were not seen in New Zealand white rabbits given the drug in doses 7 times the human dose nor in rats given 12.5 times the maximum human dose. While there are no adequate and well-controlled studies in pregnant women, there has been one report of severe congenital bony deformity, tracheoesophageal fistula, and anal atresia (Vater association) in a baby born to a woman who took dextroamphetamine sulfate with lovastatin during the first trimester of pregnancy. Dextroamphetamine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nonteratogenic Effects

Infants born to mothers dependent on amphetamines have an increased risk of premature delivery and low birth weight. Also, these infants may experience symptoms of withdrawal as demonstrated by dysphoria, including agitation, and significant lassitude.

Nursing Mothers

Amphetamines are excreted in human milk. Mothers taking amphetamines should be advised to refrain from nursing.

Pediatric Use

Long-term effects of amphetamines in pediatric patients have not been well established. Amphetamines are not recommended for use in pediatric patients under 3 years of age.

with Attention Deficit Disorder with Hyperactivity described under **INDICATIONS AND USAGE**.

Clinical experience suggests that in psychotic pediatric patients, administration of amphetamines may exacerbate symptoms of behavior disturbance and thought disorder.

Amphetamines have been reported to exacerbate motor and phonic tics and Tourette's syndrome. Therefore, clinical evaluation for tics and Tourette's syndrome in pediatric patients and their families should precede use of stimulant medications.

Data are inadequate to determine whether chronic administration of amphetamines may be associated with growth inhibition; therefore, growth should be monitored during treatment.

Drug treatment is not indicated in all cases of Attention Deficit Disorder with Hyperactivity and should be considered only in light of the complete history and evaluation of the pediatric patient. The decision to prescribe amphetamines should depend on the physician's assessment of the chronicity and severity of the pediatric patient's symptoms and their appropriateness for his/her age. Prescription should not depend solely on the presence of one or more of the behavioral characteristics.

When these symptoms are associated with acute stress reactions, treatment with amphetamines is usually not indicated.

ADVERSE REACTIONS

Cardiovascular

Palpitations, tachycardia, elevation of blood pressure. There have been isolated reports of cardiomyopathy associated with chronic amphetamine use.

Central Nervous System

Psychotic episodes at recommended doses (rare), overstimulation, restlessness, dizziness, insomnia, euphoria, dyskinesia, dysphoria, tremor, headache, exacerbation of motor and verbal tics and Tourette's syndrome.

Gastrointestinal

Dryness of the mouth, unpleasant taste, diarrhea, constipation, intestinal ischemia and other gastrointestinal disturbances. Anorexia and weight loss may occur as undesirable effects.

Allergic

Urticaria

Endocrine

Impotence, changes in libido, frequent or prolonged erections.

Musculoskeletal

Rhabdomyolysis

DRUG ABUSE AND DEPENDENCE

Controlled Substance

Zenzedi is a Schedule II controlled substance.

Abuse

Dextroamphetamine sulfate has a high potential for abuse and misuse which can lead to the development of a substance use disorder, including addiction (see WARNINGS). Dextroamphetamine sulfate can be diverted for non-medical use into illicit channels or distribution.

Abuse is the intentional non-therapeutic use of a drug, even once, to achieve a desired psychological or physiological effect. Misuse is the intentional use, for therapeutic purposes, of a drug by an individual in a way other than prescribed by a health care provider or for whom it was not prescribed. Drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that may include a strong desire to take the drug, difficulties in controlling drug use (e.g., continuing drug use despite harmful consequences, giving a higher priority to drug use than other activities and obligations), and possible tolerance or physical dependence.

Misuse and abuse of amphetamines may cause increased heart rate, respiratory rate, or blood pressure; sweating; dilated pupils; hyperactivity; restlessness; insomnia; decreased appetite; loss of coordination; tremors; flushed skin; vomiting; and/or abdominal pain. Anxiety, psychosis, hostility, aggression, and suicidal or homicidal ideation have also been observed with CNS stimulants abuse and/or misuse. Misuse and abuse of CNS stimulants, including dextroamphetamine sulfate, can result in overdose and death (see OVERDOSAGE), and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.

Dependence

Physical Dependence

Dextroamphetamine sulfate may produce physical dependence. Physical dependence is a state that develops as a result of physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dose reduction of a drug.

Withdrawal signs and symptoms after abrupt discontinuation or dose reduction following prolonged use of CNS stimulants including dextroamphetamine sulfate include dysphoric mood; depression; fatigue; vivid, unpleasant dreams; insomnia or hypersomnia; increased appetite; and psychomotor retardation or agitation.

Tolerance

Dextroamphetamine sulfate may produce tolerance. Tolerance is a physiological state characterized by a reduced response to a drug after repeated administration (i.e., a higher dose of a drug is required to produce the same effect that was once obtained at

a lower dose).

OVERDOSAGE

Clinical Effects of Overdose

Overdose of CNS stimulants is characterized by the following sympathomimetic effects:

- Cardiovascular effects including tachyarrhythmias, and hypertension or hypotension. Vasospasm, myocardial infarction, or aortic dissection may precipitate sudden cardiac death. Takotsubo cardiomyopathy may develop.
- CNS effects including psychomotor agitation, confusion, and hallucinations. Serotonin syndrome, seizures, cerebral vascular accidents, and coma may occur.
- Life-threatening hyperthermia (temperatures greater than 104°F) and rhabdomyolysis may develop.

Overdose Management

Consider the possibility of multiple drug ingestion. D-amphetamine is not dialyzable. Consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdose management recommendations.

DOSAGE AND ADMINISTRATION

Amphetamines should be administered at the lowest effective dosage and dosage should be individually adjusted. Late evening doses should be avoided because of the resulting insomnia.

Narcolepsy

Usual dose is 5 to 60 mg per day in divided doses, depending on the individual patient response. Narcolepsy seldom occurs in children under 12 years of age; however, when it does, dextroamphetamine sulfate may be used. The suggested initial dose for patients aged 6 to 12 is 5 mg daily; daily dose may be raised in increments of 5 mg at weekly intervals until an optimal response is obtained. In patients 12 years of age and older, start with 10 mg daily; daily dosage may be raised in increments of 10 mg at weekly intervals until optimal response is obtained. If bothersome adverse reactions appear (e.g., insomnia or anorexia), dosage should be reduced. Give first dose on awakening; additional doses (1 or 2) at intervals of 4 to 6 hours.

Attention Deficit Disorder with Hyperactivity

Not recommended for pediatric patients under 3 years of age.

In pediatric patients from 3 to 5 years of age, start with 2.5 mg daily; daily dosage may be raised in increments of 2.5 mg at weekly intervals until optimal response is obtained.

In pediatric patients 6 years of age and older, start with 5 mg once or twice daily; daily dosage may be raised in increments of 5 mg at weekly intervals until optimal response is obtained. Only in rare cases will it be necessary to exceed a total of 40 mg per day.

Give first dose on awakening; additional doses (1 or 2) at intervals of 4 to 6 hours.

Where possible, drug administration should be interrupted occasionally to determine if there is a recurrence of behavioral symptoms sufficient to require continued therapy.

Prior to treating patients with dextroamphetamine sulfate tablets assess:

- for the presence of cardiac disease (i.e., perform a careful history, family history of sudden death or ventricular arrhythmia, and physical exam) (see *WARNINGS*) .
- the family history and clinically evaluate patients for motor or verbal tics or Tourette's syndrome (see *WARNINGS*)

HOW SUPPLIED

Zenzedi (Dextroamphetamine Sulfate Tablets, USP) are available as:

2.5 mg:	White, square tablet, debossed "2.5" on one side and "MIA" on the other side in: Bottles of 30 tablets, NDC 24338-850-03
----------------	---

5 mg:	Pink, oval tablet, debossed "5" on one side and "MIA" score on the other side in: Bottles of 30 tablets, NDC 24338-851-03
--------------	--

7.5 mg:	Light green, triangle tablet, debossed "7.5" on one side and "MIA" on the other side in: Bottles of 30 tablets, NDC 24338-852-03
----------------	---

10 mg:	Peach, round tablet, double scored on one side and debossed "10" over "MIA" on the other side in: Bottles of 30 tablets, NDC 24338-853-03
---------------	--

15 mg:	Light blue, pentagon tablet, debossed "15" on one side and "MIA" on the other side in: Bottles of 30 tablets, NDC 24338-854-03
---------------	---

20 mg:	Purple, capsule-shaped tablet, debossed "20" on one side and "MIA" on the other side in: Bottles of 30 tablets, NDC 24338-855-03
---------------	---

30 mg:	Light yellow, hexagon tablet, debossed "30" on one side and "MIA" on the other side in: Bottles of 30 tablets, NDC 24338-856-03
---------------	--

Store at 20° to 25°C (68° to 77°F); excursions permitted 15° to 30°C (59° to 86°F).
[See *USP Controlled Room Temperature*].

Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).

KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.

DEA Order Form Required.

Pharmacist: Medication Guide to be dispensed to Patients.

Manufactured for:
Azurity Pharmaceuticals, Inc.
Woburn, MA 01801

Rev. 05/2025
ZEN-PI-10

MEDICATION GUIDE
Zenedi® (zen-Zed-ee)
(Dextroamphetamine Sulfate Tablets, USP) CII

What is the most important information I should know about Zenedi?

Zenedi may cause serious side effects, including:

- **Abuse misuse, and addiction.** Zenedi has a high chance for abuse and misuse and may lead to substance use problems, including addiction. Misuse and abuse of Zenedi, other amphetamine containing medicines, and methylphenidate containing medicines, can lead to overdose and death. The risk of overdose and death is increased with higher doses of Zenedi or when it is used in ways that are not approved, such as snorting or injection.
 - Your healthcare provider should check you or your child's risk for abuse, misuse, and addiction before starting treatment with Zenedi and will monitor you or your child during treatment.
 - Zenedi may lead to physical dependence after prolonged use, even if taken as directed by your healthcare provider.
 - Do not give Zenedi to anyone else. See "**What is Zenedi?**" for more information.
 - Keep Zenedi in a safe place and properly dispose of any unused medicine. See "**How should I store Zenedi?**" for more information.
 - Tell your healthcare provider if you or your child have ever abused or been dependent on alcohol, prescription medicines, or street drugs.
- **Risks for people with serious heart disease:** Sudden death has happened in people who have heart defects or other serious heart disease. Your healthcare provider should check you or your child carefully for heart problems before starting treatment with Zenedi. Tell your healthcare provider if you or your child have any heart problems, heart disease, or heart defects.

Call your healthcare provider right away or go to the nearest hospital emergency room right away if you or your child have any signs of heart problems such as chest pain, shortness of breath, or fainting during treatment with Zenedi.

- **Increased blood pressure and heart rate.**

Your healthcare provider should check you or your child's blood pressure and heart rate regularly during treatment with Zenzedi.

• **Mental (psychiatric) problems, including:**

- new or worse behavior or thought problems.
- new or worse bipolar illness.
- new psychotic symptoms (such as hearing voices, or seeing or believing things that are not real) or new manic symptoms.

Tell your healthcare provider about any mental problems you or your child have, or about a family history of suicide, bipolar illness, or depression.

Call your healthcare provider right away if you or your child have any new or worsening mental symptoms or problems during treatment with Zenzedi, especially hearing voices, seeing or believing things that are not real, or new manic symptoms.

What is Zenzedi?

Zenzedi is a central nervous system (CNS) stimulant prescription medicine used for the treatment of:

- a sleep disorder called narcolepsy.
- Attention-Deficit Hyperactivity Disorder (ADHD) in children 3 to 16 years of age. Zenzedi may help increase attention and decrease impulsiveness and hyperactivity in people with ADHD.

It is not known if Zenzedi is safe and effective in children under 3 years of age.

Zenzedi is a federally controlled substance (CII) because it contains dextroamphetamine that can be a target for people who abuse prescription medicines or street drugs. Keep Zenzedi in a safe place to protect it from theft.

Never give your Zenzedi to anyone else because it may cause death or harm them.

Selling or giving away Zenzedi may harm others and is against the law.

Do not take Zenzedi if you or your child:

- are allergic to amphetamine products or any of the ingredients in Zenzedi. See the end of this Medication Guide for a complete list of ingredients in Zenzedi.
- are taking or have taken within the past 14 days, a medicine used to treat depression called a monoamine oxidase inhibitor (MAOI), including the antibiotic linezolid or the intravenous medicine methylene blue.

Before taking Zenzedi, tell your healthcare provider about all of your or your child's medical conditions, including if you or your child:

- have heart problems, heart disease, heart defects, or high blood pressure.
- have mental problems including psychosis, mania, bipolar illness, or depression, or have a family history of suicide, bipolar illness, or depression.
- have seizures or have had an abnormal brain wave test (EEG).
- have circulation problems in fingers and toes.
- have or had repeated movements or sounds (tics) or Tourette's syndrome, or have a family history of tics or Tourette's syndrome.
- are pregnant or plan to become pregnant. It is not known if Zenzedi will harm the unborn baby. Tell your healthcare provider if you or your child become pregnant during treatment with Zenzedi.
- are breastfeeding or plan to breastfeed. Zenzedi passes into breast milk. You or your child should not breastfeed during treatment with Zenzedi. Talk to your healthcare provider about the best way to feed the baby during treatment with Zenzedi.

Tell your healthcare provider about all of the medicines that you or your child take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Zenedi and some medicines may interact with each other and cause serious side effects. Sometimes the doses of other medicines will need to be changed during treatment with Zenedi. Your healthcare provider will decide if Zenedi can be taken with other medicines.

Especially tell your healthcare provider if you or your child take:

- selective serotonin reuptake inhibitors (SSRIs)
- medicines used to treat migraine headaches called triptans
- lithium
- tramadol
- buspirone
- serotonin norepinephrine reuptake inhibitors (SNRIs)
- tricyclic antidepressants
- fentanyl
- tryptophan
- St. John's Wort

Know the medicines that you or your child take. Keep a list of your or your child's medicines with you to show your healthcare provider and pharmacist when you or your child get a new medicine. **Do not start any new medicine during treatment with Zenedi without talking to your healthcare provider first.**

How should Zenedi be taken?

- Take Zenedi exactly as prescribed by your or your child's healthcare provider.
- Your healthcare provider may change the dose if needed.
- Zenedi is usually taken two to three times a day. The first dose is usually taken in the morning. One or two more doses may be taken during the day, 4 to 6 hours apart.

If you or your child take too much Zenedi, call your healthcare provider or Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away.

What should I avoid while taking Zenedi?

Do not drive, operate heavy machinery, or do other potentially dangerous activities until you know how Zenedi affects you.

What are possible side effects of Zenedi?

Zenedi may cause serious side effects, including:

- See **"What is the most important information I should know about Zenedi?"**
- **Slowing of growth (height and weight) in children.** Children should have their height and weight checked often during treatment with Zenedi. Your healthcare provider may stop your child's Zenedi treatment if they are not growing or gaining weight as expected.
- **Seizures.** Your healthcare provider may stop treatment with Adderall if you or your child have a seizure.
- **Circulation problems in fingers and toes (peripheral vasculopathy, including Raynaud's phenomenon). Signs and symptoms may include:**
 - fingers or toes may feel numb, cool, painful.
 - fingers or toes may change color from pale, to blue, to red.

Tell your healthcare provider if you or your child have numbness, pain, skin color change, or sensitivity to temperature in your fingers or toes.

Call your healthcare provider right away if you or your child have any signs of unexplained wounds appearing on fingers or toes during treatment with Zenzedi.

- **New or worsening tics or worsening Tourette's syndrome.** Tell your healthcare provider if you or your child get any new or worsening tics or worsening Tourette's syndrome during treatment with Zenzedi.
- **Serotonin syndrome.** This problem may happen when Zenzedi is taken with certain other medicines and may be life-threatening. Stop taking Zenzedi and call your healthcare provider or go to the nearest hospital emergency room right away if you or your child develop any of the following signs and symptoms of serotonin syndrome:
 - agitation
 - fast heartbeat
 - flushing
 - seizures
 - coma
 - sweating
 - loss of coordination
 - confusion
 - dizziness
 - tremors, stiff muscles, or muscle twitching
 - seeing or hearing things that are not real (hallucination)
 - changes in blood pressure
 - high body temperature (hyperthermia)
 - nausea, vomiting, diarrhea

The most common side effects of Zenzedi include:

- fast heartbeat
- headache
- stomach upset
- decreased appetite
- trouble sleeping
- weight loss
- tremors
- dizziness
- dry mouth

These are not all of the possible side effects of Zenzedi.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

You may also report side effects to Azurity Pharmaceuticals, Inc., Medical Information at 1-800-461-7449.

How should I store Zenzedi?

- Store Zenzedi at room temperature between 68° to 77°F (20° to 25°C).
- Store Zenzedi in a safe place, like a locked cabinet. Protect from light.
- Dispose of remaining, unused, or expired Zenzedi by a medicine take back program

at a U.S. Drug Enforcement Administration (DEA) authorized collection site. If no take back program or DEA authorized collector is available, mix Zenzedi with an undesirable, nontoxic substance such as dirt, cat litter, or used coffee grounds to make it less appealing to children and pets. Place the mixture in a container such as a sealed plastic bag and throw away Zenzedi in the household trash. Visit www.fda.gov/drugdisposal for additional information on disposal of unused medicines.

Keep Zenzedi and all medicines out of the reach of children.

General information about the safe and effective use of Zenzedi.

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use Zenzedi for a condition for which it was not prescribed. Do not give Zenzedi to other people, even if they have the same symptoms that you or your child have. It may harm them and it is against the law. You can ask your pharmacist or healthcare provider for information about Zenzedi that is written for health professionals. For more information about Zenzedi you may also contact Azurity Pharmaceuticals, Inc. at 1-800-461-7449.

What are the ingredients in Zenzedi?

Active ingredient: dextroamphetamine sulfate

Inactive ingredients: colloidal silicon dioxide, crospovidone, microcrystalline cellulose and stearic acid. The 5 mg tablets contain D&C Red #27 and FD&C Yellow #6. The 7.5 mg tablets contain FD&C Blue #1 and D&C Yellow #10. The 10 mg tablets contain FD&C Red #40, FD&C Yellow #6 and FD&C Blue #2. The 15 mg tablets contain FD&C Blue #1, FD&C Blue #2, and FD&C Red #40. The 20 mg tablets contain FD&C Blue #1 and D&C Red #27. The 30 mg tablets also contain D&C Yellow #10.

Manufactured for:
Azurity Pharmaceuticals, Inc.,
Woburn, MA 01801
ZEN-MG-08

This Medication Guide has been approved by the U.S. Food and Drug Administration.
Revised: 05/2025

PRINCIPAL DISPLAY PANEL - 2.5 mg Tablet Bottle Label - 24338-850-03


NDC 24338-850-03
30 tablets

Zenzedi®
Dextroamphetamine
Sulfate Tablets, USP
CII

Rx only
2.5 mg

PHARMACIST: Dispense the Medication
Guide provided separately to each patient.

Mfd. for: Azurity Pharmaceuticals, Inc.,
Woburn, MA 01801

	Each tablet contains 2.5 mg Dextroamphetamine Sulfate USP. Dispense in a well-closed container as defined in the USP. USUAL DOSAGE: SEE PACKAGE INSERT. Keep this and all medications out of the reach of children. Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].	NDC 24338-850-03 30 tablets
		Zenedi® CII Dextroamphetamine Sulfate Tablets, USP
	1028A03 5/2025 ZEN-TL02-30-02	Rx only 2.5 mg PHARMACIST: Dispense the Medication Guide provided separately to each patient. Mfd. for: Azurity Pharmaceuticals, Inc. Woburn, MA 01801

PRINCIPAL DISPLAY PANEL - 5 mg Tablet Bottle Label - 24338-851-03


NDC 24338-851-03
30 tablets

Zenedi®
Dextroamphetamine Sulfate Tablets, USP
CII

Rx only
5 mg

PHARMACIST: Dispense the Medication Guide provided separately to each patient.

Mfd. for: Azurity Pharmaceuticals, Inc.,
Woburn, MA 01801

	Each tablet contains 5 mg Dextroamphetamine Sulfate USP. Dispense in a well-closed container as defined in the USP. USUAL DOSAGE: SEE PACKAGE INSERT. Keep this and all medications out of the reach of children. Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].	NDC 24338-851-03 30 tablets
		Zenedi® CII Dextroamphetamine Sulfate Tablets, USP
	1029B03 5/2025 ZEN-TL05-30-02	Rx only 5 mg PHARMACIST: Dispense the Medication Guide provided separately to each patient. Mfd. for: Azurity Pharmaceuticals, Inc. Woburn, MA 01801

PRINCIPAL DISPLAY PANEL - 7.5 mg Tablet Bottle Label - 24338-852-03

NDC 24338-852-03

30 tablets

Zenzedi®

Dextroamphetamine

Sulfate Tablets, USP


CII

Rx only

7.5 mg

PHARMACIST: Dispense the Medication
Guide provided separately to each patient.

Mfd. for: Azurity Pharmaceuticals, Inc.,
Woburn, MA 01801

	Each tablet contains 7.5 mg Dextroamphetamine Sulfate USP. Dispense in a well-closed container as defined in the USP. USUAL DOSAGE: SEE PACKAGE INSERT. Keep this and all medications out of the reach of children. Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].	NDC 24338-852-03 30 tablets
		Zenzedi®  Dextroamphetamine Sulfate Tablets, USP Rx only 7.5 mg PHARMACIST: Dispense the Medication Guide provided separately to each patient. Mfd. for: Azurity Pharmaceuticals, Inc. Woburn, MA 01801
	1169A03 5/2025 ZEN-TL07-30-02	

PRINCIPAL DISPLAY PANEL - 10 mg Tablet Bottle Label - 24338-853-03

NDC 24338-853-03

30 tablets

Zenzedi®

Dextroamphetamine

Sulfate Tablets, USP

CII

Rx only

10 mg

PHARMACIST: Dispense the Medication
Guide provided separately to each patient.

Mfd. for: Azurity Pharmaceuticals, Inc.,
Woburn, MA 01801

	<p>Each tablet contains 10 mg Dextroamphetamine Sulfate USP. Dispense in a well-closed container as defined in the USP. USUAL DOSAGE: SEE PACKAGE INSERT. Keep this and all medications out of the reach of children. Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].</p>	<p>NDC 24338-853-03 30 tablets</p> <p>Zenedi® CII Dextroamphetamine Sulfate Tablets, USP</p>
	<p>1031B03</p> <p>5/2025</p>	<p>Rx only 10 mg</p> <p>PHARMACIST: Dispense the Medication Guide provided separately to each patient.</p> <p>Mfd. for: Azurity Pharmaceuticals, Inc. Woburn, MA 01801</p>
	<p>ZEN-TL10-30-02</p>	

PRINCIPAL DISPLAY PANEL - 15 mg Tablet Bottle Label - 24338-854-03

NDC 24338-854-03

30 tablets

Zenedi®
Dextroamphetamine Sulfate Tablets, USP
CII

Rx only
15 mg

PHARMACIST: Dispense the Medication Guide provided separately to each patient.

Mfd. for: Azurity Pharmaceuticals, Inc.,
Woburn, MA 01801

	<p>Each tablet contains 15 mg Dextroamphetamine Sulfate USP. Dispense in a well-closed container as defined in the USP. USUAL DOSAGE: SEE PACKAGE INSERT. Keep this and all medications out of the reach of children. Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].</p>	<p>NDC 24338-854-03 30 tablets</p> <p>Zenedi® CII Dextroamphetamine Sulfate Tablets, USP</p>
	<p>1032A03</p> <p>5/2025</p>	<p>Rx only 15 mg</p> <p>PHARMACIST: Dispense the Medication Guide provided separately to each patient.</p> <p>Mfd. for: Azurity Pharmaceuticals, Inc. Woburn, MA 01801</p>
	<p>ZEN-TL15-30-02</p>	

PRINCIPAL DISPLAY PANEL - 20 mg Tablet Bottle Label - 24338-855-03

NDC 24338-855-03

30 tablets

Zenzedi®
Dextroamphetamine
Sulfate Tablets, USP
CII

Rx only
20 mg

PHARMACIST: Dispense the Medication
Guide provided separately to each patient.

Mfd. for: Azurity Pharmaceuticals, Inc.,
Woburn, MA 01801

Each tablet contains 20 mg Dextroamphetamine Sulfate USP.
Dispense in a well-closed container as defined in the USP.
USUAL DOSAGE: SEE PACKAGE INSERT.
Keep this and all medications out of the reach of children.
Store at 20° to 25°C (68° to 77°F); excursions permitted
to 15° to 30°C (59° to 86°F) [See USP Controlled Room
Temperature].

1033A03
5/2025
ZEN-TL20-30-02

NDC 24338-855-03 30 tablets
Zenzedi® CII
Dextroamphetamine
Sulfate Tablets, USP
Rx only **20 mg**
PHARMACIST: Dispense the Medication
Guide provided separately to each patient.
Mfd. for: Azurity Pharmaceuticals, Inc.
Woburn, MA 01801

PRINCIPAL DISPLAY PANEL - 30 mg Tablet Bottle Label - 24338-856-03


NDC 24338-856-03
30 tablets

Zenzedi®
Dextroamphetamine
Sulfate Tablets, USP
CII

Rx only
30 mg

PHARMACIST: Dispense the Medication
Guide provided separately to each patient.

Mfd. for: Azurity Pharmaceuticals, Inc.,
Woburn, MA 01801



Each tablet contains 30 mg Dextroamphetamine Sulfate USP.
 Dispense in a well-closed container as defined in the USP.
USUAL DOSAGE: SEE PACKAGE INSERT.
 Keep this and all medications out of the reach of children.
Store at 20° to 25°C (68° to 77°F); excursions permitted
 to 15° to 30°C (59° to 86°F) [See USP Controlled Room
 Temperature].

NDC 24338-856-03 30 tablets

Zenedi [Ⓜ]
 Dextroamphetamine
 Sulfate Tablets, USP

Rx only

30 mg

1170A03

5/2025

PHARMACIST: Dispense the Medication
 Guide provided separately to each patient.

Mfd. for: Azurity Pharmaceuticals, Inc.
 Woburn, MA 01801

ZEN-TL30-30-02

ZENZEDI

dextroamphetamine sulfate tablet

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:24338-850
Route of Administration	ORAL	DEA Schedule	CII

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
DEXTROAMPHETAMINE SULFATE (UNII: JJ768O327N) (DEXTROAMPHETAMINE - UNII:TZ47U051FI)	DEXTROAMPHETAMINE SULFATE	2.5 mg

Inactive Ingredients

Ingredient Name	Strength
SILICON DIOXIDE (UNII: ETJ7Z6XBU4)	
CROSPVIDONE (120 .MU.M) (UNII: 68401960MK)	
MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)	
STEARIC ACID (UNII: 4ELV7Z65AP)	

Product Characteristics

Color	WHITE	Score	no score
Shape	SQUARE	Size	7mm
Flavor		Imprint Code	25;MIA
Contains			

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:24338-850-	30 in 1 BOTTLE; Type 0: Not a Combination	02/10/2021	

03	Product	05/10/2021	
Marketing Information			
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA090533	05/31/2013	

ZENZEDI

dextroamphetamine sulfate tablet

Product Information			
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:24338-851
Route of Administration	ORAL	DEA Schedule	CII

Active Ingredient/Active Moiety			
Ingredient Name	Basis of Strength	Strength	
DEXTROAMPHETAMINE SULFATE (UNII: JJ768O327N) (DEXTROAMPHETAMINE - UNII:TZ47U051FI)	DEXTROAMPHETAMINE SULFATE	5 mg	

Inactive Ingredients		
Ingredient Name	Strength	
SILICON DIOXIDE (UNII: ETJ7Z6XBU4)		
CROSPVIDONE (120 .MU.M) (UNII: 68401960MK)		
MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)		
STEARIC ACID (UNII: 4ELV7Z65AP)		
D&C RED NO. 27 (UNII: 2LRS185U6K)		
FD&C YELLOW NO. 6 (UNII: H77VEI93A8)		

Product Characteristics			
Color	PINK	Score	2 pieces
Shape	OVAL	Size	11mm
Flavor		Imprint Code	5;MIA
Contains			

Packaging				
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:24338-851-03	30 in 1 BOTTLE; Type 0: Not a Combination Product	03/12/2021	

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA090533	05/31/2013	

ZENZEDI

dextroamphetamine sulfate tablet

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:24338-852
Route of Administration	ORAL	DEA Schedule	CII

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
DEXTROAMPHETAMINE SULFATE (UNII: JJ768O327N) (DEXTROAMPHETAMINE - UNII:TZ47U051FI)	DEXTROAMPHETAMINE SULFATE	7.5 mg

Inactive Ingredients

Ingredient Name	Strength
SILICON DIOXIDE (UNII: ETJ7Z6XBU4)	
CROSPVIDONE (120 .MU.M) (UNII: 68401960MK)	
MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)	
STEARIC ACID (UNII: 4ELV7Z65AP)	
FD&C BLUE NO. 1 (UNII: H3R47K3TBD)	
D&C YELLOW NO. 10 (UNII: 35SW5USQ3G)	

Product Characteristics

Color	GREEN (Light)	Score	no score
Shape	TRIANGLE	Size	8mm
Flavor		Imprint Code	75;MIA
Contains			

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:24338-852-03	30 in 1 BOTTLE; Type 0: Not a Combination Product	03/12/2021	

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
--------------------	--	----------------------	--------------------

ANDA	ANDA090533	05/31/2013	
------	------------	------------	--

ZENZEDI

dextroamphetamine sulfate tablet

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:24338-853
Route of Administration	ORAL	DEA Schedule	CII

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
DEXTROAMPHETAMINE SULFATE (UNII: JJ768O327N) (DEXTROAMPHETAMINE - UNII:TZ47U051FI)	DEXTROAMPHETAMINE SULFATE	10 mg

Inactive Ingredients

Ingredient Name	Strength
SILICON DIOXIDE (UNII: ETJ7Z6XBU4)	
CROSPROVIDONE (120 .MU.M) (UNII: 68401960MK)	
MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)	
STEARIC ACID (UNII: 4ELV7Z65AP)	
FD&C RED NO. 40 (UNII: WZB9127XOA)	
FD&C YELLOW NO. 6 (UNII: H77VEI93A8)	
FD&C BLUE NO. 2 (UNII: L06K8R7DQK)	

Product Characteristics

Color	ORANGE (Peach)	Score	4 pieces
Shape	ROUND	Size	8mm
Flavor		Imprint Code	10;MIA
Contains			

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:24338-853-03	30 in 1 BOTTLE; Type 0: Not a Combination Product	03/12/2021	

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA090533	05/31/2013	

ZENZEDI

dextroamphetamine sulfate tablet

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:24338-854
Route of Administration	ORAL	DEA Schedule	CII

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
DEXTROAMPHETAMINE SULFATE (UNII: JJ768O327N) (DEXTROAMPHETAMINE - UNII:TZ47U051FI)	DEXTROAMPHETAMINE SULFATE	15 mg

Inactive Ingredients

Ingredient Name	Strength
SILICON DIOXIDE (UNII: ETJ7Z6XBU4)	
CROSPVIDONE (120 .MU.M) (UNII: 68401960MK)	
MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)	
STEARIC ACID (UNII: 4ELV7Z65AP)	
FD&C BLUE NO. 1 (UNII: H3R47K3TBD)	
FD&C BLUE NO. 2 (UNII: L06K8R7DQK)	
FD&C RED NO. 40 (UNII: WZB9127XOA)	

Product Characteristics

Color	BLUE	Score	no score
Shape	PENTAGON (5 sided)	Size	8mm
Flavor		Imprint Code	15;MIA
Contains			

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:24338-854-03	30 in 1 BOTTLE; Type 0: Not a Combination Product	03/12/2021	

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA090533	05/01/2014	

ZENZEDI

dextroamphetamine sulfate tablet

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:24338-855
Route of Administration	ORAL	DEA Schedule	CII

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
DEXTROAMPHETAMINE SULFATE (UNII: JJ768O327N) (DEXTROAMPHETAMINE - UNII:TZ47U051FI)	DEXTROAMPHETAMINE SULFATE	20 mg

Inactive Ingredients

Ingredient Name	Strength
SILICON DIOXIDE (UNII: ETJ7Z6XBU4)	
CROSPVIDONE (120 .MU.M) (UNII: 68401960MK)	
MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)	
STEARIC ACID (UNII: 4ELV7Z65AP)	
FD&C BLUE NO. 1 (UNII: H3R47K3TBD)	
D&C RED NO. 27 (UNII: 2LRS185U6K)	

Product Characteristics

Color	PURPLE	Score	no score
Shape	OVAL	Size	11mm
Flavor		Imprint Code	20;MIA
Contains			

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:24338-855-03	30 in 1 BOTTLE; Type 0: Not a Combination Product	03/12/2021	

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA090533	05/01/2014	

ZENZEDI

dextroamphetamine sulfate tablet

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:24338-856
---------------------	-------------------------	---------------------------	---------------

Route of Administration	ORAL	DEA Schedule	CII	
Active Ingredient/Active Moiety				
Ingredient Name		Basis of Strength	Strength	
DEXTROAMPHETAMINE SULFATE (UNII: JJ768O327N) (DEXTROAMPHETAMINE - UNII:TZ47U051FI)		DEXTROAMPHETAMINE SULFATE	30 mg	
Inactive Ingredients				
Ingredient Name			Strength	
SILICON DIOXIDE (UNII: ETJ7Z6XBU4)				
CROSPVIDONE (120 .MU.M) (UNII: 68401960MK)				
MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)				
STEARIC ACID (UNII: 4ELV7Z65AP)				
D&C YELLOW NO. 10 (UNII: 35SW5USQ3G)				
Product Characteristics				
Color	YELLOW (light)	Score	no score	
Shape	HEXAGON (6 sided)	Size	8mm	
Flavor		Imprint Code	30;MIA	
Contains				
Packaging				
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:24338-856-03	30 in 1 BOTTLE; Type 0: Not a Combination Product	03/12/2021	
Marketing Information				
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date	
ANDA	ANDA090533	05/01/2014		

Labeler - Azurity Pharmaceuticals, Inc. (117505635)

Revised: 11/2025

Azurity Pharmaceuticals, Inc.